Rodman & Renshaw Maintains Market Outperform on Pharmacyclics

Rodman & Renshaw has published a research report on Pharmacyclics PCYC after the company made an announcement this morning that the United States Patent and Trademark Office (USPTO) has issued the company a patent covering PCI-32765. In the report, Rodman & Renshaw writes, "PCYC had previously shifted the relevant patent expiry on PCI-32765 from 2026 to 2029. This new patent could potentially move the relevant expiry back further to 2032. As a reminder, our existing model only assigns a terminal value (post-2026) of ~$215mm. Should PCYC actually be able to forestall generic entrants until 2032, PCI-32765 could potentially garner significant revenues after 2026 providing potential upside to our valuation. However, it is important to remember that any cashflow in the post-2026 timeframe would be heavily discounted even before factoring in additional potential risk of generic entrants." Rodman & Renshaw maintains its Market Outperform rating and $22 price target on Pharmacyclics, which is currently trading up $0.14 from Friday's $14.62 closing price.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorNewsReiterationLegalAnalyst RatingsRodman & RenshawUnited States Patent and Trademark Office
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!